This is a double-masked, placebo-controlled study which will determine the action of NCX 470 ophthalmic solution, 0.1% on aqueous humor dynamic parameters in healthy volunteers or subjects with OHT.

开始日期2023-12-12

申办/合作机构

Nicox Ophthalmics, Inc.

CTR20223164

/ Completed临床1期

0.1%NCX 470 滴眼液在中国健康志愿者中的全身药代动力学、安全性和耐受性研究

主要目的：评价0.1% NCX 470滴眼液单次和多次给药在中国健康受试者中的药代动力学特征次要目的：评价0.1% NCX 470滴眼液单次和多次给药在中国健康受试者中的安全性和耐受性

开始日期2023-02-22

申办/合作机构

Nicox Ophthalmics, Inc.

[+2]

NCT04630808

/ Completed临床3期

A Phase 3, Randomized, Multi-Regional, Double-Masked, Parallel-Group Trial Evaluating the Safety and Efficacy of NCX 470 0.1% vs. Latanoprost 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension (Denali)

The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.

开始日期2020-11-09

申办/合作机构

Nicox Ophthalmics, Inc.

100 项与 Bimatoprost grenod 相关的临床结果

登录后查看更多信息

100 项与 Bimatoprost grenod 相关的转化医学

登录后查看更多信息

100 项与 Bimatoprost grenod 相关的专利（医药）

登录后查看更多信息

项与 Bimatoprost grenod 相关的文献（医药）

2024-12-01·Contemporary Clinical Trials

A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study

Article

作者: Mansberger, Steven L ; Hubatsch, Doug ; Fechtner, Robert ; Lopez, Krisi

PURPOSE:

To identify the optimal dose of NCX 470, a nitric oxide (NO)-donating bimatoprost, for comparison to latanoprost in a phase 3 trial for open-angle glaucoma (OAG) or ocular hypertension (OHTN) using an adaptive dose selection design.

PATIENTS AND METHODS:

In this prospective, multicenter trial, subjects were randomized 1:1:1 to NCX 470 0.065 %, NCX 470 0.1 %, or latanoprost 0.005 % dosed topically to both eyes once daily. After at least 30 subjects were assigned to each group, interim analysis was undertaken at 2 weeks and an independent committee selected the final NCX 470 dose for the full 12-week trial.

RESULTS:

The interim analysis included 103 subjects. The least-squares mean (95 % confidence interval [CI]) difference in diurnal intraocular pressure (IOP) was -1.51 mmHg (-2.88, -0.14) in the NCX 470 0.065 % group (p = 0.0308) and - 1.71 mmHg (-3.04, -0.38) in the NCX 470 0.1 % group (p = 0.0123), both favoring NCX 470 over latanoprost. The most common side effect was conjunctival/ocular hyperemia, the frequency and severity of which were similar in both NCX 470 dosing groups (p > 0.05). NCX 470 0.1 % was selected as the final dose and the NCX 470 0.065 % dose arm was terminated with subsequent subjects randomized 1:1 to NCX 470 0.1 % or latanoprost.

CONCLUSION:

Both concentrations of the NO-donating bimatoprost NCX 470 lower IOP more than latanoprost following 2 weeks of daily therapy. This adaptive dose selection design allowed identification of the optimal dose of NCX 470 with reduced trial costs, recruitment time, and the number of patients exposed to study medication.

2024-08-01·Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics

NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm's Canal Constructs

Article

作者: Unser, Andrea ; Torrejon, Karen Y. ; Ahmed, Feryan ; Hubatsch, Douglas A ; Impagnatiello, Francesco ; Torrejon, Karen Y ; Bastia, Elena ; Hubatsch, Douglas A. ; Galli, Corinna ; Toris, Carol ; Fan, Shan

Purpose: To determine NCX 470 (0.1%) and Lumigan^® (bimatoprost ophthalmic solution, 0.01%-LUM) intraocular pressure (IOP)-lowering activity after single or repeated (5 days) dosing along with changes in aqueous humor (AH) dynamics. Methods: Ocular hypotensive activity of NCX 470 and LUM was compared with vehicle (VEH) in Beagle dogs using TonoVet^®. Non-human primates (NHP) and bioengineered three-dimensional (3D) human Trabecular Meshwork/Schlemm's Canal (HTM/HSC™) constructs exposed to transforming growth factor-β2 (TGFβ2) were used to monitor NCX 470 and LUM-induced changes in AH dynamics. Results: NCX 470 (30 μL/eye) showed greater IOP reduction compared with LUM (30 μL/eye) following single AM dosing [maximum change from baseline (CFB_max) = -1.39 ± 0.52, -6.33 ± 0.73, and -3.89 ± 0.66 mmHg (mean ± standard error of the mean) for VEH, NCX 470, and LUM, respectively]. Likewise, repeated 5 days daily dosing of NCX 470 resulted in lower IOP than LUM across the duration of the study (average IOP decrease across tests was -0.45 ± 0.22, -6.06 ± 0.15, and -3.60 ± 0.22 mmHg for VEH, NCX 470, and LUM, respectively). NCX 470 increased outflow facility (Cfl) in vivo in NHP (Cfl_VEH = 0.37 ± 0.09 μL/min/mmHg and Cfl_NCX470 = 0.64 ± 0.17 μL/min/mmHg) as well as in vitro (C_HTM/HSC) in HTM/HSC constructs (C_HTM/HSC__VEH = 0.47 ± 0.02 μL/min/mm²/mmHg and C_HTM/HSC__NCX470 = 0.76 ± 0.03 μL/min/mm²/mmHg). In addition, NCX 470 increased uveoscleral outflow (Fu_VEH = 0.62 ± 0.26 μL/min and Fu_NCX470 = 1.53 ± 0.39 μL/min with episcleral venous pressure of 15 mmHg) leaving unaltered aqueous flow (AHF_VEH = 2.03 ± 0.22 μL/min and AHF_NCX470 = 1.93 ± 0.31 μL/min) in NHP. Conclusions: NCX 470 elicits greater IOP reduction than LUM following single or repeated dosing. Data in NHP and 3D-HTM/HSC constructs suggest that changes in Cfl and Fu account for the robust IOP-lowering effect of NCX 470.

2024-08-01·AMERICAN JOURNAL OF OPHTHALMOLOGY

A Randomized, Controlled Comparison of NCX 470, a Nitric Oxide-Donating Bimatoprost, and Latanoprost in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The MONT BLANC Study

Article

作者: Mansberger, Steven ; Ziebell, Sara ; Lopez, Krisi ; Hubatsch, Doug ; Fechtner, Robert ; Mulaney, Jay ; Branch, James

PURPOSE:

To compare intraocular pressure (IOP)-lowering efficacy and safety of NCX 470, a nitric oxide (NO)-donating bimatoprost, to latanoprost in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

DESIGN:

Prospective, phase 3, randomized, adaptive dose-selection, double-masked, parallel-group trial.

METHODS:

691 subjects with OAG or OHT and unmedicated IOP ≥26 mmHg at 8AM, ≥24 mmHg at 10AM, and ≥22 mmHg at 4PM in the study eye were randomized to NCX 470 0.065%, NCX 470 0.1%, or latanoprost 0.005%. An interim analysis was performed to select the final dose of NCX 470. We evaluated noninferiority of NCX 470 versus latanoprost, based on IOP reduction from baseline at 8AM and 4PM at 2 weeks, 6 weeks, and 3 months.

RESULTS:

661 subjects were analyzed; IOP was significantly reduced at all on-treatment time points, with reductions ranging from 8.0 to 9.7 mmHg (P < .0001 at each time point) in the NCX 470 0.1% group. Mean IOP reductions were greater with NCX 470 0.1% than latanoprost 0.005% at all 6 time points and significantly greater (P < .05) at 4 of the 6 time points. The most common adverse event was conjunctival/ocular hyperemia.

CONCLUSION:

The NO-donating prostaglandin analogue NCX 470 0.1% was well-tolerated and lowered IOP more than latanoprost in subjects with OAG or OHT at all 6 time points. With a dual mechanism of action that enhances both uveoscleral and trabecular outflow, NCX 470 could become an important first-line therapy for IOP reduction in glaucoma.

108

项与 Bimatoprost grenod 相关的新闻（医药）

2025-09-04

·GlobeNewswire-Health Care

Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed

Press Release Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed Company expects to fully repay existing financial debts in 2026NCX 470 NDA submissions in U.S. (H1 2026) and subsequently in China Milestones payable on U.S. NDA submission and on approvalGlaukos extends NCX 1728 research agreement Future strategic options under consideration including collaborations or business combinationsQ&A for shareholders available on the Nicox website: Q&A September 4, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that it expects to be able to fully repay all existing financial debts in 2026 and provided an update on its portfolio and financial situation. This follows the recent announcements of the licensing of NCX 470 to Kowa, completing our global coverage, and the positive results from our second pivotal Phase 3 clinical trial, Denali. NCX 470 has met the requirements for New Drug Applications (NDA) in the U.S. and China, with NDA submission expected in H1 2026 in the U.S., and subsequently in China. Based on these submissions, the Company expects to have recurrent revenue from 2027, in addition to milestone payments on NDA submission and approval. Costs of the NDA submissions are the responsibility of our partners.“Nicox is a revenue generating biotech with a deep and proven expertise in ophthalmology development, transactions and corporate operations. Following the recent announcement of the licensing deal for NCX 470 with Kowa, which fulfils our global licensing plans, we have also completed the second pivotal Phase 3 clinical trial, Denali, for NCX 470 in the U.S. and China. Our team will be supporting our partners, Kowa and Ocumension, in submitting the NCX 470 New Drug Applications and ensuring broad communication of the product profile and data.” said Gavin Spencer, Chief Executive Officer of Nicox. “We have demonstrated that Nicox can deliver on both the development of major clinical assets and the associated financing, whilst simultaneously implementing commercial solutions. In doing so, we have created long-term revenue streams for the Company, addressed our short-term financial needs and expect to fulfil our obligations to creditors. We believe we are now in a strong position to explore strategic options, including collaborations or business combinations.”Key Future Milestones NCX 470 New Drug Application (NDA) filing in the United States: expected in H1 2026.NCX 470 New Drug Application (NDA) filing in China: expected after submission in the U.S. Results from NCX 470 Phase 3 clinical program in Japan: Program initiated in summer 2025. Managed and financed by Kowa. Financial UpdateNCX 470 is now licensed globally, with milestone payments expected in 2026 and 2027. Royalties on net sales are expected from 2027. Based on the expected upcoming milestones and the repayment of all existing financial debts, the Company is financed into Q3 2026. The Company remains committed to cost control, optimizing resource allocation while maintaining the capabilities required to support our strategic objectives. If any of the assumptions around estimated income or costs change, this may impact the cash runway of the Company.Portfolio update NCX 470, Nicox’s lead product candidate, is licensed globally to two top-tier pharma partners, Kowa and Ocumension Therapeutics. The first two Phase 3 trials, Mont Blanc and Denali, have met the requirements for submission of NDAs in the U.S. and China. U.S. – based on Nicox’s projections, an NDA with the U.S. Food and Drug Administration (FDA) is expected to be submitted in H1 2026. Kowa is responsible for the costs of the NDA submission.China – an NDA is expected to be filed with the Chinese regulatory authorities by our partner, Ocumension, after the U.S. submission. The costs of filing the NDA are the responsibility of Ocumension.Japan – a Phase 3 confirmatory efficacy and a Phase 3 safety trial have been initiated in Japanese patients. Kowa is responsible for managing the trials, at their cost, and expect to be able to file for a marketing authorisation in Japan based on these trials.Europe – the regulatory strategy is being evaluated. NCX 1728, an NO-donating PDE-5 inhibitor, is being evaluated in a pre-clinical research program exploring indications for the treatment of glaucoma, including neuroprotection, and in the treatment of retinal diseases, under an exclusive research and option to license agreement with Glaukos. Glaukos has paid an extension fee to prolong the period of evaluation of NCX 1728 for the treatment of glaucoma. Evaluation for retinal conditions is also continuing, and is subject to different option conditions.ZERVIATE® (cetirizine ophthalmic solution), 0.24%, is currently commercialized through exclusive licensing agreements in the U.S. by Harrow, Inc. and in China by Ocumension Therapeutics for ocular itching associated with allergic conjunctivitis. VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is exclusively licensed worldwide to Bausch + Lomb. Nicox sold the royalty revenue from VYZULTA to Soleus Capital in October 2024.NCX 4251: Changes in the U.S. dry eye market suggest that the investment in development may not be justified. NCX 4251 remains available for licensing outside the Chinese market.About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX). For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024” which is available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_NicoxPipelineAndStrategyUpdateSeptember2025_PR_FINAL

临床3期引进/卖出申请上市

2025-08-26

·GlobeNewswire-Health Care

Nicox Announces Shareholder Q&A Webpage Available

Press Release Nicox Announces Shareholder Q&A Webpage AvailableAugust 26, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that a new webpage “Q&A” is available on the company’s website, www.nicox.com, including information on the most frequently asked questions for shareholders in the form of a Q&A about Nicox and its business. The Q&A page can be reached here: Q&A Any investor questions can be addressed to communications@nicox.com.About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese, and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024” which is available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_Q&AAugust2025_PR_FINAL

2025-08-23

·药明康德

BMI显著下降！突破性疗法获FDA优先审评资格；创新眼药水达3期试验主要终点！上市申请即将递交……

BMI显著下降！突破性疗法获FDA优先审评资格 Rhythm Pharmaceuticals宣布，美国FDA已受理其药品setmelanotide的补充新药申请（sNDA），用于治疗继发性下丘脑性肥胖，并授予优先审评资格。该申请的PDUFA目标日期为2025年12月20日。与此同时，欧洲药品管理局（EMA）也已受理该药品扩展适应症的监管申请。Setmelanotide是一种黑皮质素-4受体（MC4R）激动剂，此前已获FDA与EMA批准，用于治疗由Bardet-Biedl综合征及POMC、PCSK1或LEPR基因缺陷导致的肥胖。该疗法曾获FDA授予突破性疗法认定，用于治疗下丘脑性肥胖。本次扩展适应症申请主要基于关键临床3期试验TRANSCEND的积极结果。这是一项全球性研究，纳入120例继发性下丘脑性肥胖患者。试验达到主要终点：setmelanotide治疗组患者在52周时平均身体质量指数（BMI）较基线下降16.5%，而安慰剂组则上升3.3%，两组间差异具有高度统计学意义（p<0.0001）。经安慰剂校正后，治疗组患者BMI降低幅度达19.8%，显示出显著且具有临床意义的疗效。创新眼药水达3期试验主要终点！上市申请即将递交 Nicox宣布，其创新一氧化氮（NO）释放型比马前列素滴眼液NCX 470 0.1%在Denali临床3期试验中达到了主要终点。在这项涵盖696例开角型青光眼或眼压过高患者的研究中，每日一次NCX 470给药在降低基线眼压（IOP）方面，与标准治疗相比，达到非劣效性。结果显示，NCX 470的眼压下降幅度为7.9至10.0 mmHg，而标准治疗为7.1至9.8 mmHg。在预设的次要疗效分析中，NCX 470在六个时间点中的五个时间点在数值上表现出优势，并在其中三个时间点达到统计学显著差异（p<0.05），尽管未能获得整体统计学上的优效性。该结果与该药物在2022年成功完成的首个3期临床试验Mont Blanc一致，进一步确认了NCX 470在降低眼压方面的疗效，为后续的监管申报奠定了坚实基础。公司表示，这一数据支持其计划于2026年上半年向美国FDA递交的新药申请（NDA）。 3.5亿美元！Kite收购体内细胞疗法公司日前，Kite宣布达成协议，将以总额高达3.5亿美元收购Interius BioTherapeutics。Interius是一家专注于体内CAR疗法开发的生物技术公司。此次收购将进一步丰富Kite在细胞治疗领域的专业能力，通过引入Interius的体内整合平台，进一步强化Kite在创新疗法领域的布局。与传统CAR-T疗法需经历细胞采集、改造及回输的繁琐流程不同，Interius的平台可直接在患者体内生成CAR-T细胞，且仅需一次静脉输注即可完成治疗，并无需预处理化疗或复杂的细胞操作。这一“现货型”且个体化的治疗方式有望实现更持久的疗效。平台的模块化架构不仅可快速应用于不同疾病领域，还能在生产规模上具备灵活性，为无法接受现有细胞疗法、尤其是病情进展迅速的患者带来新的治疗机会。参考资料： [1] Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients. Retrieved August 22, 2025 from https://www.nicox.com/wp-content/uploads/EN_NCX470DenaliToplineAugust2025_PR_FINAL.pdf [2] Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity. Retrieved August 22, 2025 from https://www.globenewswire.com/news-release/2025/08/20/3136704/0/en/Rhythm-Pharmaceuticals-Announces-FDA-Acceptance-of-sNDA-for-Setmelanotide-in-Acquired-Hypothalamic-Obesity.html [3] Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform. Retrieved August 22, 2025 from https://www.businesswire.com/news/home/20250820272168/en/Kite-to-Acquire-Interius-BioTherapeutics-to-Advance-In-Vivo-Platform 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

优先审批突破性疗法免疫疗法细胞疗法临床3期

100 项与 Bimatoprost grenod 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
高眼压症	临床3期	中国	苏州欧康维视生物科技有限公司	2022-01-30
开角型青光眼	临床3期	美国	Nicox Ophthalmics, Inc.	2020-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04630808 (Denali, NEWS) 人工标引	临床3期	开角型青光眼 \| 高眼压症	696	NCX 470 0.1%	窪製糧齋憲鹽鬱蓋範顧(餘選餘齋願觸簾淵醖鹽) = Mean IOP reductions from baseline ranged from 7.9 to 10.0 mmHg with NCX 470 0.1% compared to 7.1 to 9.8 mmHg with latanoprost, measured at 8 AM and 4 PM across week 2, week 6, and month 3 visits. In a prespecified secondary analysis, NCX 470 achieved statistically significant superiority (p<0.05) at 3 of 6 timepoints, and numerically greater reductions at 5 of 6 timepoints, with differences up to 0.8 mmHg in favor of NCX 470. 繭網獵衊糧淵獵選築艱 (夢鑰範構遞遞鏇鏇遞築 ) 更多	非劣	2025-08-21
				Latanoprost 0.005%
NCT04445519 (MONT BLANC, CTgov)	临床3期	开角型青光眼	691	NCX 470 0.1% (initial phase of trial) (NCX 470 0.1%)	蓋壓積窪鬱艱願窪齋鏇(糧鬱鑰齋艱鑰遞窪鹽衊) = 艱淵遞網窪膚夢蓋壓獵顧鑰築鹽繭蓋糧鹹憲蓋 (製襯鬱憲簾選艱構選壓, 3.443) 更多	-	2025-05-30
				Latanoprost (Latanoprost 0.005%)	蓋壓積窪鬱艱願窪齋鏇(糧鬱鑰齋艱鑰遞窪鹽衊) = 鏇鹹鏇鹽遞選廠範願襯顧鑰築鹽繭蓋糧鹹憲蓋 (製襯鬱憲簾選艱構選壓, 3.349) 更多
NCT05938699 (Whistler, GlobeNewswire) 人工标引	临床3期	高眼压症	18	NCX 470	膚窪齋顧窪構窪製艱衊(醖窪遞顧膚範窪壓憲網) = Changes in aqueous humor flow rate trended towards significance vs. placebo (p=0.072). Outflow facility was positive at 1 pm (p=0.081), significant at 3 pm (p=0.001), as was the diurnal outflow (p=0.004). 齋壓蓋淵憲鑰製獵窪獵 (壓築積願襯糧蓋壓窪簾 )	积极	2025-05-14
				Placebo
NCT04445519 (MONT BLANC, Literature) 人工标引	临床3期	开角型青光眼 \| 高眼压症	103	NCX 470NCX 470 0.065 %	艱醖糧鬱衊顧壓餘醖製(積夢積範壓鏇願鏇夢蓋) = The most common side effect was conjunctival/ocular hyperemia, the frequency and severity of which were similar in both NCX 470 dosing groups (p > 0.05). 襯艱築遞鏇獵憲顧鹽繭 (鹹築範遞範窪積鏇鏇顧 )	积极	2024-12-01
				NCX 470NCX 470 0.1 %
NCT03657797 (Dolomites, CTgov)	临床2期	开角型青光眼	656	NCX 470 (NCX 470 0.021%)	鹹選範選憲構窪壓鏇築(繭淵鏇積鹽淵夢觸製獵) = 鹹積鏇齋衊夢鹹憲製鹹鑰壓網衊醖築蓋鑰繭獵 (蓋醖繭窪醖簾範憲觸壓, 2.606) 更多	-	2022-12-08
				NCX 470 (NCX 470 0.042%)	鹹選範選憲構窪壓鏇築(繭淵鏇積鹽淵夢觸製獵) = 壓夢鑰積衊簾膚醖淵齋鑰壓網衊醖築蓋鑰繭獵 (蓋醖繭窪醖簾範憲觸壓, 2.511) 更多
NCT04445519 (Mont Blanc, Corporate Publications) 人工标引	临床3期	青光眼	691	NCX 470	壓鑰糧餘襯憲淵壓範鬱(觸齋壓選願觸醖願製積) = 憲艱糧遞膚壓壓窪觸構艱範簾廠衊觸簾繭積選 (憲鹽顧襯遞鑰衊餘製簾 ) 更多	非劣	2022-10-31
				Latanoprost	壓鑰糧餘襯憲淵壓範鬱(觸齋壓選願觸醖願製積) = 壓餘餘網憲鹹齋顧鹽壓艱範簾廠衊觸簾繭積選 (憲鹽顧襯遞鑰衊餘製簾 ) 更多
NCT03657797 (Dolomites, AAO2020)	临床2期	低眼压	433	NCX 470 0.021%	願鹽齋憲鹹網選憲網觸(壓選淵積觸艱繭鏇艱窪) = The most common adverse event was conjunctival hyperemia. There were no treatment-related serious adverse events or treatment-related systemic adverse events 獵襯淵蓋選構鹹壓餘壓 (襯選繭鏇廠憲壓夢鬱鬱 )	积极	2020-11-13
				NCX 470 0.065%
NCT03657797 (Dolomites, GlobeNewswire) 人工标引	临床2期	青光眼	433	NCX-470	膚遞鏇遞艱鬱醖獵鬱鹽(製淵齋範鹽艱製積蓋淵) = 範淵積夢獵鹹選選範顧獵鏇鹽繭窪糧繭築憲廠 (夢齋餘襯窪獵鹽繭顧膚 ) 更多	积极	2019-10-02
				Latanoprost	膚遞鏇遞艱鬱醖獵鬱鹽(製淵齋範鹽艱製積蓋淵) = 觸齋積範觸築鹹艱繭壓獵鏇鹽繭窪糧繭築憲廠 (夢齋餘襯窪獵鹽繭顧膚 ) 更多